Critical limb ischemia (CLI) is the most advanced stage of peripheral arterial disease. It is clinically defined as rest pain with or without skin ulcer or gangrene and carries a very poor prognosis with a high rates of limb amputation and cardiovascular mortality. Despite the first definition of CLI has been published more than 30 years ago, the debate about what it really is, is still open. Over the years the hemodynamic parameters utilised to define the critical level of limb perfusion have changed. This has raised some question about the apparent confusion about the definition of CLI. Moreover, a new term such as "limb threatening ischemia" has replaced the definition of CLI in recent guideline. Therefore, it becomes necessary to understand the evolution of the concept and the definition of CLI, to interpret the future trend.Hence, this work analysing the guideline documents on peripheral arterial disease that have defined the CLI to date, aims to clarify the path that has brought to the current conceptual changes of the definition of CLI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3233/CH-190576 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chemiluminescent Probe for Enhanced Visualization of Renal Ischemia-Reperfusion Injury via Pyroglutamate Aminopeptidase-1 Activation.
Anal Chem
January 2025
Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
The absence of an effective imaging tool for diagnosing renal ischemia-reperfusion injury (RIRI) severely delays its treatment, and currently, no definitive clinical interventions are available. Pyroglutamate aminopeptidase-1 (PGP-1), a potential inflammatory cytokine, has shown considerable potential as a biomarker for tracing the inflammatory process in vivo. However, its exact role in the enhanced visualization of RIRI in complex biological systems has yet to be fully established.
View Article and Find Full Text PDF2021 JAPAN Chronic Limb Threatening Ischemia Database (JCLIMB) Annual Report.
Ann Vasc Dis
December 2024
Since 2013, the Japanese Society for Vascular Surgery has started the project of nationwide registration and tracking database for patients with critical limb ischemia (CLI) who are treated by vascular surgeons. The purpose of this project is to clarify the current status of the medical practice for patients with CLI to contribute to the improvement of the quality of medical care. This database is created on the National Clinical Database (NCD) and collects data on patients' backgrounds, therapeutic measures, early results, and long-term prognoses as long as 5 years after the initial treatment.
View Article and Find Full Text PDFAnalysis of in-hospital deaths in patients with critical limb ischemia necessitating invasive treatments: based on a Japanese nationwide database.
Cardiovasc Interv Ther
October 2024
Department of Health Data Science, Graduate School of Data Science, Yokohama City University, 22-2 Seto, Kanazawa, Yokohama, Kanagawa, Japan.
Critical limb ischemia (CLI) is associated with systemic cardiovascular and non-cardiovascular diseases. Treatments primarily targeting limb-related outcomes may not improve overall life prognosis. We aimed to describe in-hospital mortality and the underlying etiologies in Japanese patients with CLI.
View Article and Find Full Text PDFCharacterization of cardiovascular serious adverse events after bypass or endovascular revascularization for limb-threatening ischemia in the BEST-CLI trial.
J Vasc Surg
September 2024
Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, Boston, MA.
Article Synopsis
- The BEST-CLI trial studied two ways to treat a serious blood flow problem called CLTI using surgery and special tubes (endovascular).
- The researchers looked at serious bad events related to the heart and blood vessels that happened within 30 days after the treatment.
- They found that both types of treatments had similar rates of heart-related problems, but the endovascular method had a slightly higher rate of blood vessel problems.
Association of race/ethnicity and patient care experiences with receipt of definitive treatment among prostate cancer survivors: a SEER-CAHPS study.
Cancer Causes Control
April 2024
Department of Pharmacy Practice, Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, 72205, USA.
Article Synopsis
- The study examined how race/ethnicity and patient care experiences (PCEs) affect treatment for older adults with localized prostate cancer in the U.S.
- It analyzed data from a large sample of men aged 65 and older, focusing on the timing and type of definitive treatment received following their diagnosis.
- While no overall racial/ethnic disparities in treatment were found, non-Hispanic Black patients were less likely to receive surgery compared to non-Hispanic White patients, highlighting the need for further research on these differences.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!